Format

Send to

Choose Destination
BJU Int. 2018 Dec;122(6):1049-1065. doi: 10.1111/bju.14362. Epub 2018 Jun 6.

Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.

Author information

1
Emeritus Professor of Urology, Universidad Autónoma de Madrid, Madrid, Spain.
2
Urology Department, IDIBAPS, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
3
Urology Department, Instituto de Salud Integral del Varón, Fundación Investigación 12 de Octubre, Hospital Universitario 12 de Octubre, Madrid, Spain.
4
Urology Department, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Navarra, Spain.
5
Urology Department, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain.
6
Urology Department, Departamento Clínico, Facultad de Ciencias Biomédicas, Hospital Universitario de Getafe, Universidad Europea de Madrid, Laureate Universities, Getafe, Madrid, Spain.
7
Urology Department, Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, Spain.
8
Llefià Primary Care Center, Badalona, Barcelona, Spain.
9
Urology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
10
San Andrés Primary Care Center, Madrid, Spain.
11
Menasalbas Primary Care Center, Toledo, Spain.
12
Urology Department, Complejo Hospitalario Universitario de Granada, Granada, Spain.
13
Pierre Fabre Ibérica S.A., Barcelona, Spain.
14
CIBER Epidemiología y Salud Pública, REGICOR Study Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Grup d'Epidemiologia i Genètica Cardiovasculars (EGEC), Barcelona, Spain.
15
Insight Consulting and Research, Mataró, Spain.
16
Department of Urology, University of Messina, Messina, Italy.

Abstract

OBJECTIVES:

To comprehensively evaluate the efficacy and safety of the hexanic extract of Serenoa repens (HESr, Permixon® ; Pierre Fabre Médicament, Castres, France), at a dose of 320 mg daily, as monotherapy for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH).

MATERIALS AND METHODS:

We conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) and prospective observational studies in patients with LUTS/BPH identified through searches in Medline, Web of Knowledge (Institute for Scientific Information), Scopus, the Cochrane Library, and bibliographic references up to March 2017. Articles studying S. repens extracts other than Permixon were excluded. Data were collected on International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax ), nocturia, quality of life, prostate volume, sexual function, and adverse drug reactions (ADRs). Data obtained from RCTs and observational studies were analysed jointly and separately using a random effects model. A sub-group analysis was performed of studies that included patients on longer-term treatment (≥1 year).

RESULTS:

Data from 27 studies (15 RCTs and 12 observational studies) were included for meta-analysis (total N = 5 800). Compared with placebo, the HESr was associated with 0.64 (95% confidence interval [CI] -0.98 to -0.31) fewer voids/night (P < 0.001) and an additional mean increase in Qmax of 2.75 mL/s (95% CI 0.57 to 4.93; P = 0.01). When compared with α-blockers, the HESr showed similar improvements on IPSS (weighted mean difference [WMD] 0.57, 95% CI -0.27 to 1.42; P = 0.18) and a comparable increase in Qmax to tamsulosin (WMD -0.02, 95% CI -0.71 to 0.66; P = 0.95). Efficacy assessed using the IPSS was similar after 6 months of treatment between the HESr and 5α-reductase inhibitors (5ARIs). Analysis of all available published data for the HESr showed a mean improvement in IPSS from baseline of -5.73 points (95% CI -6.91 to -4.54; P < 0.001). HESr did not negatively affect sexual function and no clinically relevant effect was observed on prostate-specific antigen. Prostate volume decreased slightly. Similar efficacy results were seen in patients treated for ≥1 year (n = 447). The HESr had a favourable safety profile, with gastrointestinal disorders being the most frequent ADR (mean incidence of 3.8%).

CONCLUSION:

The present meta-analysis, which includes all available RCTs and observational studies, shows that the HESr (Permixon) reduced nocturia and improved Qmax compared with placebo and had a similar efficacy to tamsulosin and short-term 5-ARI in relieving LUTS. HESr (Permixon) appears to be an efficacious and well-tolerated therapeutic option for the long-term medical treatment of LUTS/BPH.

KEYWORDS:

Serenoa repens ; LUTS/BPH; Permixon; hexanic extract; meta-analysis; systematic review

PMID:
29694707
DOI:
10.1111/bju.14362

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center